Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved..
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer (MBC) was published in 2021. A special, hybrid guidelines meeting was convened by ESMO and the Korean Society of Medical Oncology (KSMO) in collaboration with nine other Asian national oncology societies in May 2022 in order to adapt the ESMO 2021 guidelines to take into account the differences associated with the treatment of MBC in Asia. These guidelines represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with MBC representing the oncological societies of China (CSCO), India (ISMPO), Indonesia (ISHMO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO). The voting was based on the best available scientific evidence and was independent of drug access or practice restrictions in the different Asian countries. The latter were discussed when appropriate. The aim of these guidelines is to provide guidance for the harmonisation of the management of patients with MBC across the different regions of Asia, drawing from data provided by global and Asian trials whilst at the same time integrating the differences in genetics, demographics and scientific evidence, together with restricted access to certain therapeutic strategies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
ESMO open - 8(2023), 3 vom: 05. Juni, Seite 101541 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Im, S-A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ESMO |
|---|
| Anmerkungen: |
Date Completed 03.07.2023 Date Revised 16.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.esmoop.2023.101541 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356814386 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356814386 | ||
| 003 | DE-627 | ||
| 005 | 20231226071249.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.esmoop.2023.101541 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1189.xml |
| 035 | |a (DE-627)NLM356814386 | ||
| 035 | |a (NLM)37178669 | ||
| 035 | |a (PII)S2059-7029(23)00767-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Im, S-A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.07.2023 | ||
| 500 | |a Date Revised 16.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer (MBC) was published in 2021. A special, hybrid guidelines meeting was convened by ESMO and the Korean Society of Medical Oncology (KSMO) in collaboration with nine other Asian national oncology societies in May 2022 in order to adapt the ESMO 2021 guidelines to take into account the differences associated with the treatment of MBC in Asia. These guidelines represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with MBC representing the oncological societies of China (CSCO), India (ISMPO), Indonesia (ISHMO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO). The voting was based on the best available scientific evidence and was independent of drug access or practice restrictions in the different Asian countries. The latter were discussed when appropriate. The aim of these guidelines is to provide guidance for the harmonisation of the management of patients with MBC across the different regions of Asia, drawing from data provided by global and Asian trials whilst at the same time integrating the differences in genetics, demographics and scientific evidence, together with restricted access to certain therapeutic strategies | ||
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ESMO | |
| 650 | 4 | |a Pan-Asian | |
| 650 | 4 | |a guidelines | |
| 650 | 4 | |a metastatic breast cancer | |
| 650 | 4 | |a treatment | |
| 700 | 1 | |a Gennari, A |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Y H |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, J H |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Z-F |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, S |e verfasserin |4 aut | |
| 700 | 1 | |a Fadjari, T H |e verfasserin |4 aut | |
| 700 | 1 | |a Tamura, K |e verfasserin |4 aut | |
| 700 | 1 | |a Mastura, M Y |e verfasserin |4 aut | |
| 700 | 1 | |a Abesamis-Tiambeng, M L T |e verfasserin |4 aut | |
| 700 | 1 | |a Lim, E H |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, C-H |e verfasserin |4 aut | |
| 700 | 1 | |a Sookprasert, A |e verfasserin |4 aut | |
| 700 | 1 | |a Parinyanitikul, N |e verfasserin |4 aut | |
| 700 | 1 | |a Tseng, L-M |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, S-C |e verfasserin |4 aut | |
| 700 | 1 | |a Caguioa, P |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, M |e verfasserin |4 aut | |
| 700 | 1 | |a Naito, Y |e verfasserin |4 aut | |
| 700 | 1 | |a Hukom, R A |e verfasserin |4 aut | |
| 700 | 1 | |a Smruti, B K |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, S-S |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, S B |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, K-H |e verfasserin |4 aut | |
| 700 | 1 | |a Ahn, H K |e verfasserin |4 aut | |
| 700 | 1 | |a Peters, S |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, T W |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshino, T |e verfasserin |4 aut | |
| 700 | 1 | |a Pentheroudakis, G |e verfasserin |4 aut | |
| 700 | 1 | |a Curigliano, G |e verfasserin |4 aut | |
| 700 | 1 | |a Harbeck, N |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ESMO open |d 2016 |g 8(2023), 3 vom: 05. Juni, Seite 101541 |w (DE-627)NLM266189539 |x 2059-7029 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2023 |g number:3 |g day:05 |g month:06 |g pages:101541 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.esmoop.2023.101541 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2023 |e 3 |b 05 |c 06 |h 101541 | ||